Science and Research

EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease

BACKGROUND: Synchronous oligometastatic disease (sOM) has been described as a distinct disease entity; however, there is no consensus on OM definition (OM-d) in non-small-cell lung cancer (NSCLC). A consensus group was formed aiming to agree on a common OM-d that could be used in future clinical trials. A European survey was circulated to generate questions and input for the consensus group meeting. METHODS: A European Organisation for Research and Treatment of Cancer Lung Cancer Group (LCG)/sOM-d consensus group survey was distributed to LCG, sOM-d consensus group, and several European thoracic oncology societies' members. RESULTS: 444 responses were analysed (radiation oncologist: 55% [n = 242], pulmonologist: 15% [n = 66], medical oncologist: 14% [n = 64]). 361 physicians (81%) aimed to cure sOM NSCLC patients and 82% (n = 362) included the possibility of radical intent treatment in their sOM-d. The maximum number of metastases considered in sOM-d varied: 12% replied 1 metastasis, 42% /= 5 metastases. 79% (n = 353) stated that number of organs involved was important for sOM-d, and most (80%, n = 355) considered that only
  • Levy, A.
  • Hendriks, L. E. L.
  • Berghmans, T.
  • Faivre-Finn, C.
  • GiajLevra, M.
  • GiajLevra, N.
  • Hasan, B.
  • Pochesci, A.
  • Girard, N.
  • Greillier, L.
  • Lantuejoul, S.
  • Edwards, J.
  • O'Brien, M.
  • Reck, M.
  • Besse, B.
  • Novello, S.
  • Dingemans, A. C.
  • Eortc Lung Cancer Group
  • Keywords

    • Consensus
    • Non-small cell lung cancer
    • Oligometastasis
    Publication details
    DOI: 10.1016/j.ejca.2019.09.012
    Journal: Eur J Cancer
    Pages: 109-114 
    Work Type: Original
    Location: ARCN
    Disease Area: LC
    Partner / Member: Ghd
    Access-Number: 31671363
    See publication on PubMed

    DZL Engagements

    chevron-down